Screening of the myelin protein zero gene in patients with Charcot-Marie-Tooth disease

被引:0
|
作者
Nowakowski, A
Kochanski, A
机构
[1] Polish Acad Sci, Med Res Ctr, Neuromuscular Unit, PL-02106 Warsaw, Poland
[2] Univ Agr, Interdisciplinary Dept Biotechnol, Warsaw, Poland
关键词
Charcot-Marie-Tooth disease; MPZ gene; SSCP; heteroduplex analysis;
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The myelin protein zero gene (MPZ) coding for the most abundant protein of the peripheral myelin was shown to be mutated in Charcot-Marie-Tooth type 1B disease (CMT1B). Later on MPZ mutations have been shown in axonal type of CMT (CMT2). Recently three novel MPZ gene mutations were reported in congenital hypomyelinating neuropathy (CHN). In contrast to the previously reported studies, focused on CMT1B disease, we aimed to analyze the coding and promoter sequences of the MPZ gene in a group of patients with three CMT phenotypes i.e.: CMT1, CMT2 and CHN. Over 500 PCR products were screened by single strand conformation polymorphism analysis (SSCP) and heteroduplex analysis (HA). In one CMT2 family we founded the E56K mutation in the MPZ gene and in one CHN patient the T124K substitution was detected. In agreement with previously reported studies we conclude that MPZ gene screening should be performed for wide phenotype spectrum of CMT.
引用
收藏
页码:273 / 280
页数:8
相关论文
共 50 条
  • [21] A novel myelin protein zero mutation associated with Charcot-Marie-Tooth type II disease.
    Di Maria, E
    Cassandrini, D
    Balestra, P
    Manganelli, F
    Santoro, L
    Ajmar, F
    Mandich, P
    Bellone, E
    AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (04) : 597 - 597
  • [22] Expression of peripheral myelin protein zero in sural nerve of patients with Charcot-Marie-Tooth disease 1B
    Tachi, N
    Kozuka, N
    Ohya, K
    Chiba, S
    Sasaki, K
    Uyemura, K
    PEDIATRIC NEUROLOGY, 2001, 24 (01) : 33 - 35
  • [23] Myelin protein zero gene dose dependent axonal ion-channel dysfunction in a family with Charcot-Marie-Tooth disease
    Moldovan, Mihai
    Pisciotta, Chiara
    Pareyson, Davide
    Krarup, Christian
    CLINICAL NEUROPHYSIOLOGY, 2020, 131 (10) : 2440 - 2451
  • [24] The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study
    Fabrizi, Gian Maria
    Tamburin, Stefano
    Cavallaro, Tiziana
    Cabrini, Ilaria
    Ferrarini, Moreno
    Taioli, Federica
    Magrinelli, Francesca
    Zanette, Giampietro
    CLINICAL NEUROPHYSIOLOGY, 2018, 129 (01) : 21 - 32
  • [25] Upregulation of large myelin protein zero leads to Charcot-Marie-Tooth disease-like neuropathy in mice
    Otani, Yoshinori
    Ohno, Nobuhiko
    Cui, Jingjing
    Yamaguchi, Yoshihide
    Baba, Hiroko
    COMMUNICATIONS BIOLOGY, 2020, 3 (01)
  • [26] Structural bases for the Charcot-Marie-Tooth disease induced by single amino acid substitutions of myelin protein zero
    Sakakura, Masayoshi
    Tanabe, Mikio
    Mori, Masaki
    Takahashi, Hideo
    Mio, Kazuhiro
    STRUCTURE, 2023, 31 (11) : 1452 - 1462.e4
  • [27] Late-onset axonal Charcot-Marie-Tooth disease:: five patients carrying a novel myelin protein zero mutation
    Laura, M.
    Milani, M.
    Morbin, M.
    Moggio, M.
    Ripolone, M.
    Jann, S.
    Scaioli, V.
    Ciano, C.
    Taroni, E.
    Pareyson, D.
    JOURNAL OF NEUROLOGY, 2006, 253 : 9 - 10
  • [28] Peripheral Myelin Protein 22 Gene Mutations in Charcot-Marie-Tooth Disease Type 1E Patients
    Jung, Na Young
    Kwon, Hye Mi
    Nam, Da Eun
    Tamanna, Nasrin
    Lee, Ah Jin
    Kim, Sang Beom
    Choi, Byung-Ok
    Chung, Ki Wha
    GENES, 2022, 13 (07)
  • [29] Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene
    Stojkovic, T
    de Seze, J
    Dubourg, O
    Arne-Bes, MC
    Tardieu, S
    Hache, JC
    Vermersch, P
    CLINICAL NEUROPHYSIOLOGY, 2003, 114 (09) : 1609 - 1614
  • [30] Charcot-Marie-Tooth disease
    Gregory T. Carter
    Michael D. Weiss
    Jay J. Han
    Phillip F. Chance
    John D. England
    Current Treatment Options in Neurology, 2008, 10 : 94 - 102